学术探索
学术期刊
新闻热点
数据分析
智能评审

The structure and function of Francisella lipopolysaccharide

被引：103
作者：
Gunn, John S.
Ernst, Robert K.
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Microbial Interface Biol, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Mol Virol, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Infect Dis, Columbus, OH 43210 USA
[5] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA
来源：
FRANCISELLA TULARENSIS: BIOLOGY, PATHOGENICITY, EPIDEMIOLOGY, AND BIODEFENSE | 2007年 / 1105卷
关键词：
LPS; lipopolysaccharide; gray variant; phase variation; LPS modification; LPS structure; lipid A; O-antigen;
D O I：
10.1196/annals.1409.006
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
A key factor in the biology of Francisella spp. is lipopolysaccharide (LPS). Francisella LPS has many unique structural properties and poorly activates proinflammatory responses due to its lack of interaction with toll-like receptor 4 (TLR4). The LPS of this organism can be modified by various carbohydrates including glucose, mannose and galactosamine, which affect various aspects of virulence. Spontaneously occurring colony variants of F. tularensis have altered LPS. This altered LPS may account for the novel phenotypes of these variants that include effects on susceptibility to killing by normal human serum, intracellular survival and animal virulence. Mutants devoid of O-antigen (directed mutants in O-antigen biosynthetic genes) show reduced intracellular survival and mouse virulence. Thus, this surface component is important in F. tularensis pathogenesis, and the inability of the LPS to alarm the immune system coupled with its frequent modification/alteration likely aid the success of this pathogen during human infection.
引用
收藏
页码：202 / 218
页数：17
相关论文
共 52 条
[1]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]   Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins [J].
Ancuta, P ;
Pedron, T ;
Girard, R ;
Sandstrom, G ;
Chaby, R .
INFECTION AND IMMUNITY, 1996, 64 (06) :2041-2046
[3]   GROWTH OF FRANCISELLA-SPP IN RODENT MACROPHAGES [J].
ANTHONY, LSD ;
BURKE, RD ;
NANO, FE .
INFECTION AND IMMUNITY, 1991, 59 (09) :3291-3296
[4]   Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents [J].
Baldridge, JR ;
McGowan, P ;
Evans, JT ;
Cluff, C ;
Mossman, S ;
Johnson, D ;
Persing, D .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1129-1138
[5]   Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines [J].
Baldridge, JR ;
Crane, RT .
METHODS, 1999, 19 (01) :103-107
[6]   Structure of the LpxC deacetylase with a bound substrate-analog inhibitor [J].
Coggins, BE ;
Li, XC ;
McClerren, AL ;
Hindsgaul, O ;
Raetz, CRH ;
Zhou, P .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (08) :645-651
[7]   Immunologic consequences of Francisella tularensis live vaccine strain infection:: Role of the innate immune response in infection and immunity [J].
Cole, Leah E. ;
Elkins, Karen L. ;
Michalek, Suzanne M. ;
Qureshi, Nilofer ;
Eaton, Linda J. ;
Rallabhandi, Prasad ;
Cuesta, Natalia ;
Vogel, Stefanie N. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (11) :6888-6899
[8]  
Conlan J Wayne, 2004, Expert Rev Vaccines, V3, P307
[9]   Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen [J].
Conlan, JW ;
Shen, H ;
Webb, A ;
Perry, MB .
VACCINE, 2002, 20 (29-30) :3465-3471
[10]   Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production [J].
Cowley, SC ;
Myltseva, SV ;
Nano, FE .
MOLECULAR MICROBIOLOGY, 1996, 20 (04) :867-874
123456